UConn startup QMD develops broad-spectrum antiviral drugs with indications ranging from herpes viruses to SARS-CoV2, the pathogen responsible for COVID-19. Read more.
Antibodies to the virus that causes COVID-19 are universal in survivors of the illness, but their ability to counteract the virus varies significantly. Read more.